In the context of MHC expression in cancer, scRNA‐seq offers a unique advantage in characterizing MHC heterogeneity by quantifying MHC gene expression at the single‐cell level, thereby distinguishing MHC‐deficient tumour subclones and dissecting the diverse MHC expression patterns among immune cells within the tumour microenvironment—an essential step toward understanding immune evasion and optimizing personalized immunotherapy.182. The gene discussed is HLA-C; the disease is neoplasm.